PureTech Health Announces Positive Data from LYT-200 Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
PureTech Health announced positive topline data from the completed Phase 1b clinical trial of LYT-200, a fully human anti-galectin-9 monoclonal antibody, in heavily pretreated patients with relapsed/refractory high-risk myelodysplastic syndrome and R/R acute myeloid leukemia. Based on the results, PureTech's Founded Entity, Gallop Oncology, has selected a recommended Phase 2 dose and intends to engage with the U.S. Food and Drug Administration to discuss the design of a subsequent trial that could potentially support registration of LYT-200 in R/R HR-MDS.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
